GlassScriptPhysician profile
Mrinalini Krishnan
NPI 1255686978
$111,197.46
in general payments reported to CMS, 2019-2025
14 companies · $42K in 2025
The $42K reported for 2025 was more than what 91% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,188 · 2020: $201 · 2021: $196 · 2022: $5,331 · 2023: $21K · 2024: $40K · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $65K · Consulting Fee: $22K · Travel and Lodging: $8,087 · Food and Beverage: $6,589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65,415.00 |
| Consulting Fee | $22,190.00 |
| Travel and Lodging | $8,087.37 |
| Food and Beverage | $6,589.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $94,338.54 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| United Therapeutics Corporation | $10,183.11 | 2021-2025 | Tyvaso, Remodulin, Orenitram |
| Abbott Laboratories | $3,535.46 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Medtronic Vascular, INC. | $1,162.44 | 2019 | |
| Abiomed | $954.79 | 2019-2023 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $361.81 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $195.13 | 2023-2025 | Winrevair |
| Sandoz INC. | $140.11 | 2021-2025 | Treprostinil |
| Medtronic, INC. | $129.97 | 2023 | Linq II |
| Lexicon Pharmaceuticals, INC. | $70.03 | 2023-2024 | Inpefa |
| E.R. Squibb & Sons, L.L.C. | $46.09 | 2023-2024 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $39.51 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $22.48 | 2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $17.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mrinalini Krishnan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.